Linklaters advises QIA on its investment in China-based biopharmaceutical company Oricell Therapeutics

Linklaters advised Qatar Investment Authority (QIA) on its investment in Oricell Therapeutics Company Limited (Oricell), a China-based innovative biopharmaceutical company focussing on the development of novel immunotherapeutics.

Oricell has raised US$45m in this Series B-1 financing round led by QIA and RTW Investments. The new injection of capital will be utilised primarily to support the company's core product clinical development in the US.

The Linklaters team was led by Singapore-based private equity partner Robert Elliot, with support from managing associate Robert Jefferies and Zhao Sheng Law Firm’s managing associate Benran Huang. The successful completion of this transaction consolidates Linklaters’ long-standing reputation for providing seamlessly integrated Chinese and international legal advice to clients through its joint operation with Zhao Sheng Law Firm.

Partner Robert Elliot commented:

“We are delighted to continue supporting QIA on its strategic investments. We have worked with Zhao Sheng as one team on many landmark transactions across Asia, where our integrated Chinese and international law advice is essential and we congratulate QIA and other parties on closing this funding round. We look forward to continuing to work with QIA on other strategic opportunities in the future.”